Unlike FDG-PET, BMIPP SPECT is less affected by blood substrates (glucose, cholesterol, fatty acids, insulin, etc.), and has the advantage that it can be evaluated both in cases with diabetes or dyslipidemia and in noncomplicated cases. The gene discussed is INS; the disease is metabolic syndrome.